Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer
February 28, 2023 07:30 ET
|
Incyclix Bio
– INX-315 is a novel, potent and selective inhibitor of CDK2 with compelling pre-clinical efficacy and safety data– First-in-human, Phase 1/2 study of INX-315 in patients with ER+/HER2- breast...
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
March 31, 2022 07:30 ET
|
Incyclix Bio
Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid Subramony, Ph.D., of Boxer Capital to join Incyclix Bio’s board of directors RESEARCH...